Meeting on the Med 2021 | Looking ahead in the cell & gene therapy sector

Mike Lehmicke, Director of Science & Industry Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses some of the exciting recent developments in the cell and gene therapy sector, including advancements made in allogeneic therapies for oncology, the potential induced pluripotent stem cell (iPSC) technology holds and how novel manufacturing technologies and process analytics could help drive the field forward in the future. He also discusses the impact of the COVID-19 and what the field can learn from the pandemic to accelerate progress in cell and gene therapy. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.